APOLLOHOSP · NSE
Apollo Hospitals Enterprise Limited
₹8,944.5
+2.01% (+₹176)
Prev. close
₹8,768.5
Volume
3,44,265
Delivery %
75.7%
As of
18 Sept 2026
Price history
Analyst sentiment
Analysts lean bullish
2 analyst stances · last 90 days · one per analyst
Trackable
1 · 1 bull / 0 neutral / 0 bear
Long-Horizon
none in window
Commentary
1 · 1 bull / 0 neutral / 0 bear
Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded
Analyst opinions
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Maintained a 'Buy' rating on Apollo Hospitals with a revised target price of ₹9,350 per share. The brokerage noted stron…” | Prabhudas Lilladher AnalysisPrabhudas Lilladher | Apollo Hospitals | NOT GRADED |
Market commentary · 1 · levels, conditionals, previews, macro & hedged views — context, not graded
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Bullish on Apollo Hospitals, with a target price of ₹10,120, indicating a 17% upside. The brokerage expects 18% YoY sale…” | Motilal Oswal AnalysisMotilal Oswal Financial Services | Apollo Hospitals | NOT GRADED |
Fundamentals
About Apollo Hospitals Enterprise Limited
Apollo Hospitals Enterprise Limited, together with its subsidiaries, provides healthcare services in India. It operates through Healthcare Services, Retail Health & Diagnostics, Digital Health & Pharmacy Distribution, and Others segments. The company's healthcare facilities comprise primary, secondary, and tertiary care, as well as specialty facilities. It offers services in cardiac sciences, oncology, neurosciences, gastroenterology, orthopedics, urology, organ transplantation, pulmonology, obstetrics and gynecology, internal medicine, vascular surgery, pediatrics, cosmetology, emergency medicine, bariatric surgery, general surgery, colorectal surgery, dentistry, nephrology, dermatology, endocrinology, preventive medicine, interventional radiology, ophthalmology, and integrative medicine, as well as robotic surgery and genomics. The company also provides project consultancy, medical educational institutes, Medvarsity for e-learning, and research services, as well as acts as an agent for life, general, and health insurance. In addition, it operates hospitals, pharmacies, primary care clinics, and diagnostic centers; short stay facilities, boutique birthing centers, multi-specialty clinics, dental and dialysis facilities, and preventive care; day surgery, diabetes management, and cradle and fertility centers; and Apollo 24/7, a digital health mobile platform that provides teleconsultations, online pharmacy deliveries, home diagnostics, and insurance services. Further, the company engages in the business of bio-banking of tissues. It serves patients, corporate clients, and the government and public sectors. Apollo Hospitals Enterprise Limited was incorporated in 1979 and is based in Chennai, India.
Details
Sector
Healthcare
Industry
Medical Care Facilities
CEO
Dr. Prathap Chandra Reddy FCCP, FICA, FRCS, M.D., MBBS
Headquarters
Chennai
Employees
44,008
Website
apollohospitals.comExchange
View on NSE ↗Key stats
Market cap
₹1.26 L Cr
P/E ratio (TTM)
60.4
Dividend yield
0.23%
EPS (TTM)
₹145.23
Beta (1Y · daily vs NIFTY 50)
0.50
Beta (5Y · monthly vs NIFTY 50)
0.64
Shares float
9.96 Cr
EPS · quarter ended Jun 2026
₹40.37
Upcoming earnings
05 Nov 2026
Financial Performance
01 · Financials
FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹10,560.01 Cr | ₹14,662.64 Cr | ₹16,612.45 Cr | ₹19,059.20 Cr | ₹21,794.00 Cr | ₹25,228.50 Cr | |
| EBITDA | ₹1,182.40 Cr | ₹2,263.26 Cr | ₹2,072.80 Cr | ₹2,477.60 Cr | ₹3,219.10 Cr | ₹3,893.10 Cr |
| ₹150.00 Cr | ₹1,055.61 Cr | ₹819.07 Cr | ₹898.60 Cr | ₹1,445.90 Cr | ₹1,941.70 Cr | |
| Diluted EPS | ₹10.74 | ₹73.42 | ₹56.97 | ₹62.5 | ₹100.56 | ₹134.94 |
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹11,416.70 Cr | ₹13,269.30 Cr | ₹14,427.80 Cr | ₹16,742.00 Cr | ₹20,644.00 Cr | ₹22,183.00 Cr | |
| ₹4,159.80 Cr | ₹4,068.10 Cr | ₹4,332.40 Cr | ₹5,332.60 Cr | ₹5,419.20 Cr | ₹8,492.40 Cr | |
| Stockholders' equity | ₹4,602.50 Cr | ₹5,623.30 Cr | ₹6,197.40 Cr | ₹6,936.00 Cr | ₹8,212.00 Cr | ₹9,480.00 Cr |
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹1,273.48 Cr | ₹1,615.64 Cr | ₹1,377.05 Cr | ₹1,920.30 Cr | ₹2,136.40 Cr | ₹2,855.70 Cr | |
| Investing cash flow | ₹-872.34 Cr | ₹-790.73 Cr | ₹-870.60 Cr | ₹-1,537.10 Cr | ₹-3,380.60 Cr | ₹-2,148.20 Cr |
| ₹-340.08 Cr | ₹-767.70 Cr | ₹-633.33 Cr | ₹-311.20 Cr | ₹1,316.80 Cr | ₹-477.60 Cr | |
| Capital expenditure | ₹-295.49 Cr | ₹-657.17 Cr | ₹-1,128.00 Cr | ₹-1,137.00 Cr | ₹-1,713.00 Cr | ₹-1,962.00 Cr |
| End cash position | ₹425.20 Cr | ₹546.50 Cr | ₹433.40 Cr | ₹505.50 Cr | ₹578.10 Cr | ₹811.30 Cr |
Debt issued, Debt repaid have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21 | Dec 21–Dec 24(13Q) | Mar 25–Jun 25(2Q) | Sep 25–Jun 26(4Q) |
|---|---|---|---|---|
| Promoter | 29.82% | 29.33% | 29.34% | 28.02% |
| Public | 70.18% | 70.67% | 70.66% | 71.98% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Aurobindo Pharma Limited | ₹97,238.87 Cr | ₹1,734 | 26.4 | 2.57 | 9.2% | 0.21 | +6.4% | +53.6% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 30
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
25 indices
Weight is a free-float market-cap-share estimate from NSE’s live index data, not NSE’s own published (and sometimes capped) index weight. Indices without a live weight feed are listed without one, in alphabetical order after the weighted ones.
Apollo Hospitals Enterprise consolidated net profit rises 34.17% in the June 2026 quarter
Business Standard · 1 month ago
There's A Lot To Like About Apollo Hospitals Enterprise's (NSE:APOLLOHOSP) Upcoming ₹10.00 Dividend
simplywall.st · 1 month ago